ArticleAnnals of medicine2025

Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.

Jiaming Zhu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.